{{Rsnum
|rsid=12678919
|Chromosome=8
|position=19986711
|Orientation=plus
|GMAF=0.101
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 80.5 | 15.9 | 3.5
| HCB | 81.8 | 17.5 | 0.7
| JPT | 81.4 | 17.7 | 0.9
| YRI | 82.3 | 17.7 | 0.0
| ASW | 78.9 | 21.1 | 0.0
| CHB | 81.8 | 17.5 | 0.7
| CHD | 77.1 | 22.0 | 0.9
| GIH | 82.2 | 17.8 | 0.0
| LWK | 91.8 | 7.3 | 0.9
| MEX | 89.7 | 10.3 | 0.0
| MKK | 89.7 | 10.3 | 0.0
| TSI | 78.4 | 18.6 | 2.9
| HapMapRevision=28
}}

G allele is associated with 2.44mg/dl increase in [[HDL cholesterol]] (good cholesterol). {{PMID|18193043}}

{{PMID Auto GWAS
|PMID=19060906
|Trait=HDL cholesterol
|Title=Common variants at 30 loci contribute to polygenic dyslipidemia
|RiskAllele=G
|Pval=2E-34
|OR=0.23
|ORtxt=[0.17-0.29] SD increase
|OA=1
}}

{{PharmGKB
|RSID=rs12678919
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19060906; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at 30 loci contribute to polygenic dyslipidemia. (Initial Sample Size: 19,840 individuals; Replication Sample Size: Up to 20,623 individuals); (Region: 8p21.3; Reported Gene(s): LPL; Risk Allele: rs12678919-G); (p-value= 2E-34).This variant is associated with HDL cholesterol.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740238
}}

{{PharmGKB
|RSID=rs12678919
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19060906; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at 30 loci contribute to polygenic dyslipidemia. (Initial Sample Size: 19,840 individuals; Replication Sample Size: Up to 20,623 individuals); (Region: 8p21.3; Reported Gene(s): LPL; Risk Allele: rs12678919-G); (p-value= 2E-41).This variant is associated with Triglycerides.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740265
}}

{{PMID Auto GWAS
|PMID=20686565
|Trait=None
|Title=Biological, clinical and population relevance of 95 loci for blood lipids.
|RiskAllele=G
|Pval=0
|OR=13.6400
|ORtxt=None
|OA=1
}}

{{PMID|19951432|OA=1
}} Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.

{{PMID|20385819|OA=1
}} Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.

{{PMID|20385826|OA=1
}} Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12678919
|overall_frequency_n=8
|overall_frequency_d=128
|overall_frequency=0.0625
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=8
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto GWAS
  |PMID=22916037
  |Trait=Metabolite levels
  |Title=Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis.
  |RiskAllele=
  |Pval=9E-13
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{PMID Auto
|PMID=24223199
|Title=Association of HDL-Related Loci with Age-Related Macular Degeneration and Plasma Lutein and Zeaxanthin: the Alienor Study
|OA=1
}}

{{PMID Auto
|PMID=22815349
|Title=Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}